Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer
Introduction: ZLDI-8, which has a relatively strong antitumor activity, is an inhibitor of ADAM-17 and acts on the Notch signaling pathway. To further optimize its structure and improve its activity, a series of derivatives of ZLDI-8 was synthesized. NY-2 was the most effective derivative based on p...
Main Authors: | Yingshi Zhang, Chang Xu, Xiangbo Xu, Lingxiang Ma, Ruolan Li, Zihua Xu, Qingchun Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1074576/full |
Similar Items
-
Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2022-03-01) -
Textkritik och ny filologi i exegetisk undervisning
by: David Davage
Published: (2023-08-01) -
Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study
by: Shunsuke Kondo, et al.
Published: (2024-01-01) -
HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
by: Wenjie Gong, et al.
Published: (2022-02-01) -
In kashgarli / ny / voice
by: Gökçen DURUKOĞLU
Published: (2021-06-01)